Icon (NASDAQ:ICLR) CFO Nigel Bernard John Clerkin Sells 1,488 Shares of Company Stock

Icon Plc (NASDAQ:ICLR) CFO Bernard Clerkin sold 1,488 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $206.66, for a total value of $307,510.08. Following the transaction, the chief financial officer directly owned 7,171 shares in the company, valued at $1,481,958.86. The trade was a 17.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nigel Bernard John Clerkin also recently made the following trade(s):

• On Tuesday, August 11th, Bernard Clerkin sold 2,267 shares of Icon stock. The stock was sold at an average price of $164.29, for a total value of $372,445.43.

Icon Stock Performance

Shares of ICLR opened at $203.77 on Wednesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.32 and a quick ratio of 1.32. Icon Plc has a one year low of $66.57 and a one year high of $219.04. The firm has a market capitalization of $15.60 billion, a P/E ratio of 35.07, a PEG ratio of 11.53 and a beta of 1.19. The business has a fifty day moving average of $173.23 and a 200 day moving average of $146.72.

Icon (NASDAQ:ICLR) last posted its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.62 by $0.04. The company had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.01 billion. Icon had a return on equity of 7.73% and a net margin of 5.45%. Icon’s revenue was down .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.31 earnings per share. As a group, sell-side analysts anticipate that Icon Plc will post 9.57 EPS for the current year.

Analyst Upgrades and Downgrades

ICLR has been the topic of several recent research reports. Barclays increased their price objective on shares of Icon from $175.00 to $230.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 29th. TD Cowen boosted their target price on shares of Icon from $197.00 to $254.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. Mizuho set a $228.00 target price on shares of Icon in a report on Friday. Royal Bank Of Canada upped their target price on shares of Icon from $185.00 to $226.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. Finally, William Blair upgraded shares of Icon to a “strong-buy” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $213.76.

Institutional Trading of Icon

Several hedge funds have recently bought and sold shares of the stock. Maple Rock Capital Partners Inc. boosted its holdings in Icon by 257.8% in the 2nd quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after buying an additional 864,300 shares during the period. Sound Shore Management Inc. CT purchased a new stake in Icon in the 1st quarter worth $69,379,000. Trinity Street Asset Management LLP increased its stake in Icon by 27.1% in the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock worth $266,725,000 after buying an additional 327,314 shares in the last quarter. Principal Financial Group Inc. increased its stake in Icon by 10.3% in the 1st quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock worth $366,481,000 after buying an additional 310,236 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Icon by 50.8% during the first quarter. Dimensional Fund Advisors LP now owns 788,828 shares of the medical research company’s stock valued at $87,262,000 after acquiring an additional 265,858 shares during the period. Institutional investors own 95.61% of the company’s stock.

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.